A Trial of HRS-5965 Capsule in Primary IgA Nephropathy — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Trial of HRS-5965 Capsule in Primary IgA Nephropathy — Stella

Recruiting

Back to Primary IgA Nephropathy trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

China

Peking University First Hospital, Beijing, Beijing Municipality

Key details

Phase

Large-scale testing

Sponsor

Chengdu Suncadia Medicine Co., Ltd.

Enrollment target

~378 participants

Started

June 2025

Primary completion

October 2027

Age range

18 Years and older

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov